Evidence map›Paper›PMID 42801600›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A BSCB-Penetrating Nanoplatform for Enhanced Luteolin Delivery in PRMT2-Targeted Epigenetic Therapy of Spinal Cord Injury.

Yixuan Wang, Bo Jin, Shipian Li, Qianxi Ouyang, Yu Xiao, Jiaxin Wen, Yehua Lai, Ping Wang, Yongjun Wang, Xuejun Cui and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yixuan Wang *Spine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Bo Jin *Shanghai Key Laboratory of Functional Materials Chemistry, East China University of Science and Technology, Shanghai, China.
Shipian LiSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-4213-2039
Qianxi OuyangSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yu XiaoSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jiaxin WenSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yehua LaiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ping WangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-1078-899X
Yongjun WangSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID https://orcid.org/0009-0003-4836-839X
Xuejun CuiSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Weian ZhangShanghai Key Laboratory of Functional Materials Chemistry, East China University of Science and Technology, Shanghai, China.ORCID https://orcid.org/0000-0002-1717-597X
Min YaoSpine Disease Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-0410-7900

Funding

National Key R&D Program of China 2024YFC3507401National Major Science and Technology Projects of China 2025ZD1801400National Natural Science Foundation of China 82074454National Natural Science Foundation of China 82374476Ningbo Top Medical and Health Research Program 2025021425Shanghai Oriental Talents Program
6 · The paper itself

Abstract

Spinal cord injury (SCI) is a devastating disorder of the central nervous system (CNS) leading to irreversible neurological deficits. Effective pharmacotherapy remains elusive, due to the restrictive blood-spinal cord barrier (BSCB), underscoring the urgent need for targeted and efficient drug delivery strategies. Luteolin (LUT), a natural flavonoid with potent anti-neuroinflammatory properties, presents a promising therapeutic option; however, it is compromised by poor solubility, low bioavailability, and limited BSCB penetration. Drawing inspiration from the traditional Chinese medicine concept of the "orifice-opening" effect of borneol (BO), we developed BO-modified mesoporous silica nanoparticles (MSN-BO@LUT) for targeted LUT delivery to the spinal cord. MSN-BO@LUT significantly enhanced LUT delivery to the spinal cord, achieving a 286.36-fold increase over LUT, and maintained a concentration of 802.17 ng/mL at 24 h. MSN-BO@LUT demonstrated robust anti-neuroinflammatory and neuroprotective effects in SCI mice, reducing microglial infiltration, promoting functional recovery, and showing favorable efficacy and safety compared with the positive control methylprednisolone. Mechanistically, released LUT targets protein arginine N-methyltransferase, reduces toll-like receptor 4 methylation, and inhibits nuclear factor kappa B-mediated pro-inflammatory signaling, thereby suppressing microglial M1 polarization. These findings suggest that MSN-BO@LUT not only provides a developed, safe, effective nanotherapeutic strategy for SCI treatment but also serves as a translatable template for developing precision nanomedicines targeting CNS disorders.

Indexed as

blood‐spinal cord barrierluteolinPRMT2spinal cord injury

Identifiers

PMID42801600
PMCPMC13616406

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.